Bio-Thera’s Anti VEGF Therapy for w-AMD Meets Phase III Endpoint, Prepares for Market Filing
— Reported by DengYueMed On June 24, 2024, Bio-Thera Solutions, Ltd. announced that its anti VEGF humanized monoclonal antibody BAT5906 has successfully met the primary endpoint in a pivotal Phase III clinical trial for the…